Researchers identify new enzyme to fight Alzheimer's disease

September 17, 2012

An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme—known as BACE2—destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease. The findings were published online Sept. 17 in the science journal Molecular Neurodegeneration.

Alzheimer's disease is the most common . It affects more that 5.5 million people in the United States. Despite the disorder's enormous financial and personal toll, effective treatments have not yet been found.

The Mayo research team, led by Malcolm A. Leissring, Ph.D., a neuroscientist at Mayo Clinic in Florida, made the discovery by testing hundreds of enzymes for the ability to lower beta-amyloid levels. BACE2 was found to lower beta-amyloid more effectively than all other enzymes tested. The discovery is interesting because BACE2 is closely related to another enzyme, known as BACE1, involved in producing beta-amyloid.

"Despite their close similarity, the two enzymes have completely opposite effects on beta-amyloid—BACE1 giveth, while BACE2 taketh away," Dr. Leissring says.

Beta-amyloid is a fragment of a larger protein, known as APP, and is produced by enzymes that cut APP at two places. BACE1 is the enzyme responsible for making the first cut that generates beta-amyloid. The research showed that BACE2 cuts beta-amyloid into smaller pieces, thereby destroying it, instead. Although other enzymes are known to break down beta-amyloid, BACE2 is particularly efficient at this function, the study found.

Previous work had shown that BACE2 can also lower beta-amyloid levels by a second mechanism: by cutting APP at a different spot from BACE1. BACE2 cuts in the middle of the beta-amyloid portion, which prevents beta-amyloid production.

"The fact that BACE2 can lower beta-amyloid by two distinct mechanisms makes this enzyme an especially attractive candidate for to treat Alzheimer's disease," says first author Samer Abdul-Hay, Ph.D., a neuroscientist at in Florida.

The discovery suggests that impairments in BACE2 might increase the risk of Alzheimer's disease. This is important because certain drugs in clinical use—for example, antiviral drugs used to treat human immunodeficiency virus (HIV)—work by inhibiting enzymes similar to BACE2.

Although BACE2 can lower beta-amyloid by two distinct mechanisms, only the newly discovered mechanism—beta-amyloid destruction—is likely relevant to the disease, the researchers note. This is because the second mechanism, which involves BACE2 cutting APP, does not occur in the brain. The researchers have obtained a grant from the National Institutes of Health to study whether blocking beta-amyloid destruction by BACE2 can increase the risk for Alzheimer's disease in a mouse model of the disease.

Explore further: Road block as a new strategy for the treatment of Alzheimer's

Related Stories

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Amyloid beta in the brain of individuals with Alzheimer's disease

March 30, 2012
While there may not be a consensus whether deposition of amyloid beta contributes to Alzheimer's disease or is a consequence of it, there is agreement that something else is promoting the process. Other proteins are often ...

Scientists uncover new ways to stimulate pancreatic beta cell growth

September 6, 2011
One of the holy grails in diabetes research is to discover molecules that stimulate beta cell growth and to find drugs that target these molecules. Now, JDRF-funded researchers in collaboration with the pharmaceutical company ...

New findings contradict dominant theory in Alzheimer's disease

October 28, 2011
For decades the amyloid hypothesis has dominated the research field in Alzheimer's disease. The theory describes how an increase in secreted beta-amyloid peptides leads to the formation of plaques, toxic clusters of damaged ...

Recommended for you

Thinking 'out-of-the-box' may build a better brain and prevent dementia

September 25, 2017
More than 5 million Americans today are affected by Alzheimer's disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million ...

Multi-gene test predicts Alzheimer's better than APOE E4 alone

September 22, 2017
A new test that combines the effects of more than two dozen genetic variants, most associated by themselves with only a small risk of Alzheimer's disease, does a better job of predicting which cognitively normal older adults ...

Personality changes don't precede clinical onset of Alzheimer's, study shows

September 21, 2017
For years, scientists and physicians have been debating whether personality and behavior changes might appear prior to the onset of Alzheimer's disease and related dementias.

Newly ID'd role of major Alzheimer's gene suggests possible therapeutic target

September 20, 2017
Nearly a quarter century ago, a genetic variant known as ApoE4 was identified as a major risk factor for Alzheimer's disease—one that increases a person's chances of developing the neurodegenerative disease by up to 12 ...

Is the Alzheimer's gene the ring leader or the sidekick?

September 15, 2017
The notorious genetic marker of Alzheimer's disease and other forms of dementia, ApoE4, may not be a lone wolf.

Potential noninvasive test for Alzheimer's disease

September 6, 2017
In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer's disease and distinguishing between different types of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.